['metabolism and nutrition disorder', 'obesity']
['semaglutide', 'liraglutide', 'placebo']

        Inclusion Criteria: - Informed consent obtained before any trial-related activities.
        Trial-related activities are any procedures that are carried out as part of the trial,
        including activities to determine suitability for the trial - Male or female, age 18 years
        or older at the time of signing inform consent - Body mass index (BMI) equal or above 30.0
        kg/m^2 at the screening visit - At least one unsuccessful weight loss attempt per
        investigator judgement Exclusion Criteria: - A HbA1c (glycosylated haemoglobin) equal to or
        above 6.5% at screening or diagnosed with type 1 or type 2 diabetes mellitus - Treatment
        with glucose lowering agent(s) within 90 days before screening - Screening calcitonin equal
        to or above 50 ng/L (pg/mL) - Personal or family history of medullary thyroid carcinoma or
        multiple endocrine neoplasia syndrome type 2 - History of pancreatitis (acute or chronic) -
        Obesity induced by endocrine disorders (e.g. Cushing Syndrome) - Treatment with any
        medication within 90 days before screening that based on investigator's judgement may cause
        significant weight change - Previous surgical treatment for obesity (liposuction and/or
        abdominoplasty performed 1 year before screening is allowed) - History of major depressive
        disorder within 2 years before randomisation - Any lifetime history of a suicidal attempt -
        Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing
        potential and not using an adequate contraceptive method (adequate contraceptive measures
        as required by local regulation or practice)
      